The European landscape for gene therapies in orphan diseases: 6-year experience with the EMA Committee for Orphan Medicinal ProductsGloria M. Palomo, Segundo Mariz, Tomás Pose‐Boirazian et al.|Molecular Therapy|2023Cited by 15
Advancing rare disease treatment: EMA’s decade-long insights into engineered adoptive cell therapy for rare cancers and orphan designationMaria Elisabeth Kalland, Segundo Mariz, Enrico Costa et al.|Gene Therapy|2024Cited by 8
Addressing global regulatory challenges in rare disease drug developmentEnrico Costa, Steffen Thirstrup, Violeta Stoyanova‐Beninska et al.|Drug Discovery Today|2025Cited by 8